Table 3.

Assessment of Health Related Quality of Life and Treatment Satisfaction Surveys during treatment with Facilitated Subcutaneous Immunoglobulin Therapy

n median (25–75%)	Baseline	2-4th months	5-8th months	9-12th months
KINDL-Children	11 53.9 (48.1–59.1)	9 60.1 (53.6–63.7)	5 60.1 (58.3–75.3)	6 69.3 (62.9–73.8)
KINDL-Parents	12 47.5 (44.7–52.4)	10 49.3 (42.6–59.9)	6 57.3 (52.1–65.6)	6 69.3 (62.9–73.8)
SF-36	7 55.1 (53.5–68.4)	6 72.5 (57.2–83.5)	3 78.9 (54.3–81.9)	2 81.9 (80.4–83.5)
TSQM-9	16 68 (48–88.5)	18 83 (64–90)	9 88* (72–92)	8 88** (73.5–93)

KINDL, Kinder Lebensqualitätsfragebogen: Children's Quality of Life Questionnaire; SF-36, Short Form 36; TSQM-9, Treatment Satisfaction Questionnaire for Medication-9

Statistical analysis involved the use of the Friedman test, followed by post-hoc analyses using the Durbin-Conover method. Bonferroni correction has been applied. Significant differences were not detected in KINDL-Child, KINDL-Parents and SF-36 (p = 0.363, 0.120, 0.112)

In TSQM-9 (p = 0.003), however, in pairwise comparisons, there was a significant difference between *baseline vs. 5-8th months (p = 0.006), ** baseline vs. 9-12th months (p < 0.001)